EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Targeted Therapy in Psoriatic Arthritis, Including Juvenile Psoriatic Arthritis: Efficacy and Safety of TNF-alpha, IL-17 and JAK Inhibitors - A Literature Review

Agnieszka Anna Gaczoł, Gabriela Piotrowska, Paulina Kopcińska, Magdalena Mortka, Hubert Bednarz, Michał Kawa, Kamil Idzik, Dominika Grzybowska, Aleksander Urbaś, Zuzanna Lechowska, Tomasz Kilian, Michał Kurnik und 1 weitere

Quality in Sport · 08.08.2026 · 66 · 73985

DOI: 10.12775/qs.2026.66.73985 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Quality in Sport, online erschienen am 08.08.2026. Verfasst von Agnieszka Anna Gaczoł und 12 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Psoriatic arthritis (PsA) and juvenile psoriatic arthritis (JPsA) are chronic inflammatory diseases with heterogeneous, multi-domain presentation; targeted therapies against TNF-alpha, IL-17 and the JAK-STAT pathway have expanded treatment options.

Aim

To evaluate efficacy and safety of three classes of targeted therapies in PsA and JPsA: TNF-alpha inhibitors (TNF-i), IL-17 inhibitors (IL-17-i) and Janus kinase inhibitors (JAK-i).Material and methods: A narrative PubMed (MEDLINE) review of phase I-III randomized trials and open-label extensions, real-world studies, and selected reviews assessing efficacy and safety of TNF-i, IL-17-i and JAK-i in adults and children with PsA/JPsA.

Results

Anti-TNF therapies show high ACR response rates, favourable skin effects, and inhibition of radiographic progression, with acceptable long-term safety. IL-17-i provide sustained improvement across major PsA domains, particularly in TNF-i-naive patients, with a stable safety profile. JAK-i are effective after failure of conventional and biologic treatment, improving joint activity, function and quality of life, but carry a characteristic adverse-event profile requiring assessment. Real-world analyses in PsA and axial spondyloarthritis show no significantly increased cardiovascular or malignancy risk with JAK-i versus anti-TNF/anti-IL-17 therapies, though rheumatoid arthritis data warrant caution in high-risk patients. In JPsA, TNF-i remain the principal biologic class, while anti-IL-17 trials confirm efficacy and safety in children.

Conclusions

Targeted therapy of PsA and JPsA requires individualization based on phenotype, prior treatment, and cardiovascular, thromboembolic and oncologic risk. Further paediatric studies are needed to define each class's role in JPsA management.

Zitieren

APA

Gaczoł, A. A., Piotrowska, G., Kopcińska, P., Mortka, M., Bednarz, H., Kawa, M., Idzik, K., Grzybowska, D., Urbaś, A., Lechowska, Z., Kilian, T., Kurnik, M., & Grzyb-Kurnik, W. (2026). Targeted Therapy in Psoriatic Arthritis, Including Juvenile Psoriatic Arthritis: Efficacy and Safety of TNF-alpha, IL-17 and JAK Inhibitors - A Literature Review. Quality in Sport, 66, 73985. https://doi.org/10.12775/qs.2026.66.73985

Vancouver

Gaczoł AA, Piotrowska G, Kopcińska P, Mortka M, Bednarz H, Kawa M, et al. Targeted Therapy in Psoriatic Arthritis, Including Juvenile Psoriatic Arthritis: Efficacy and Safety of TNF-alpha, IL-17 and JAK Inhibitors - A Literature Review. Quality in Sport. 2026;66:73985. doi:10.12775/qs.2026.66.73985

BibTeX
@article{Gaczo2026,
  author = {Gaczoł, Agnieszka Anna and Piotrowska, Gabriela and Kopcińska, Paulina and Mortka, Magdalena and Bednarz, Hubert and Kawa, Michał and Idzik, Kamil and Grzybowska, Dominika and Urbaś, Aleksander and Lechowska, Zuzanna and Kilian, Tomasz and Kurnik, Michał and Grzyb-Kurnik, Weronika},
  title = {Targeted Therapy in Psoriatic Arthritis, Including Juvenile Psoriatic Arthritis: Efficacy and Safety of TNF-alpha, IL-17 and JAK Inhibitors - A Literature Review},
  journal = {Quality in Sport},
  year = {2026},
  volume = {66},
  pages = {73985},
  doi = {10.12775/qs.2026.66.73985}
}
Kostenlos starten →